Diagnostic Workup and First-Line Treatment for Periodic Limb Movement Disorder
For periodic limb movement disorder (PLMD), obtain polysomnography to document >15 events/hour in adults (>5/hour in children), measure serum ferritin and transferrin saturation in all patients, and initiate intravenous ferric carboxymaltose 1000 mg as first-line therapy when ferritin ≤100 ng/mL or transferrin saturation <20%, followed by gabapentinoids if symptoms persist after iron repletion. 1, 2
Diagnostic Workup
Polysomnographic Criteria
- PLMD requires polysomnography demonstrating frequent periodic limb movements during sleep (PLMS): >15 events/hour in adults or >5 events/hour in children. 1
- The movements must be associated with clinically significant sleep disturbance or daytime dysfunction that cannot be better explained by another disorder. 1
- PLMD is a diagnosis of exclusion—you must rule out conditions commonly associated with PLMS including restless legs syndrome (RLS), untreated obstructive sleep apnea, REM sleep behavior disorder, and narcolepsy. 1
- PLMS show high night-to-night variability and typically occur during the first 4 hours of sleep, with movements lasting 0.5–10 seconds and recurring every 15–30 seconds. 1
Mandatory Laboratory Assessment
- Measure serum ferritin and transferrin saturation in every patient with suspected PLMD, ideally in the morning after avoiding iron-containing supplements and foods for at least 24 hours. 1, 2
- Iron repletion thresholds: ferritin ≤100 ng/mL or transferrin saturation <20% should trigger treatment in PLMD patients. 2 (Note: The adult RLS threshold is ferritin ≤75 ng/mL, but the higher 100 ng/mL threshold reflects brain iron requirements.) 1, 2
- In adolescents presenting with anemia, mean corpuscular hemoglobin ≈24 pg confirms hypochromia and supports iron-deficiency anemia diagnosis. 2
Medication and Comorbidity Review
- Discontinue medications that exacerbate limb movements: serotonergic antidepressants (especially mirtazapine and venlafaxine), dopamine antagonists (antipsychotics and antiemetics), and centrally acting antihistamines. 2, 3
- Screen for obstructive sleep apnea when clinically indicated, as it can independently cause PLMS. 2
First-Line Treatment
Iron Repletion (Primary Intervention)
When ferritin ≤100 ng/mL or transferrin saturation <20%:
- Intravenous ferric carboxymaltose 1000 mg is the strongly recommended first-line iron therapy for PLMD, providing rapid, complete restoration of iron stores without gastrointestinal side effects. 2
- Alternative IV formulations (ferumoxytol or low-molecular-weight iron dextran) are conditionally recommended when ferric carboxymaltose is unavailable. 2
- Oral ferrous sulfate 325–650 mg daily (or every other day) is conditionally recommended when intravenous access is problematic, though it is slower to correct deficiency and commonly causes constipation—the leading cause of discontinuation. 2
- IV iron produces noticeable improvement in PLMS and symptoms within weeks, whereas oral iron requires 4–12 weeks for gradual improvement. 2
Pharmacologic Therapy When Iron Repletion Is Insufficient
If symptoms persist after adequate iron repletion or while awaiting iron response:
- Gabapentinoids receive strong recommendations as first-line pharmacologic therapy for PLMD: 2
Critical Pitfall to Avoid
- Do not use dopamine agonists (pramipexole, ropinirole, rotigotine) as first-line therapy—they carry a 7–10% annual risk of augmentation (iatrogenic worsening of the disorder) and are explicitly advised against by the 2025 AASM guidelines. 2
Adjunctive Lifestyle Measures
- Avoid caffeine and alcohol, maintain good sleep hygiene, and address positional discomfort or joint issues that may mimic or worsen symptoms. 2
Treatment Algorithm for PLMD
Confirm diagnosis with polysomnography (PLMS index >15/hour in adults, >5/hour in children) and exclude RLS, sleep apnea, REM behavior disorder, and narcolepsy. 1
Measure iron studies (ferritin and transferrin saturation) in all patients. 1, 2
If ferritin ≤100 ng/mL or TSAT <20%: Initiate IV ferric carboxymaltose 1000 mg (or oral ferrous sulfate if IV unavailable). 2
Review and discontinue RLS/PLMD-exacerbating medications. 2
If symptoms persist after iron repletion or immediate pharmacologic control is needed: Start a gabapentinoid (gabapentin enacarbil, gabapentin, or pregabalin). 2
For refractory cases: Consider low-dose opioid therapy (e.g., methadone 5–10 mg daily) as the next step. 2
Special Considerations in Children
- Pediatric PLMD prevalence is low (0.3%), requiring meticulous investigation to exclude mimics such as growing pains, leg cramps, and behavioral issues. 4
- Diagnostic criteria are the same (PLMS index >5/hour), but children may have difficulty describing symptoms, and comorbidities like ADHD are common. 4, 5
- Iron supplementation is the mainstay of pediatric treatment, with behavioral interventions and off-label pharmacologic options reserved for severe cases. 5
- A proposed new diagnostic category, "Sleep Leg Movement Disorder of Childhood" (SLMDC), may better capture the spectrum of pediatric limb movement disorders, including non-periodic movements. 5
Evidence Quality and Nuances
The 2025 AASM guideline 1 represents the most recent and authoritative source, with strong recommendations for gabapentinoids and IV iron based on systematic review. 1, 2 The World Sleep Society partially endorsed these recommendations, noting regional variations in medication availability (e.g., gabapentin enacarbil is not universally accessible) and divergent treatment traditions regarding dopamine agonists. 6 However, the core principle—avoiding dopamine agonists as first-line therapy due to augmentation risk—received strong global consensus. 6
The periodic leg movement index has high sensitivity but low specificity, underscoring the importance of strict adherence to diagnostic criteria and exclusion of other sleep disorders. 4 PLMS are nonspecific and occur in normal individuals, so the diagnosis of PLMD requires both polysomnographic findings and clinically significant consequences. 1, 7